Eli Lilly’s Trulicity Approved for Reducing Cardiovascular Events

Eli Lilly’s Trulicity (dulaglutide) received the FDA’s approval for reducing cardiovascular events in adults with and without established cardiovascular disease.

The approval was based on the results of a clinical trial in which Trulicity showed a significant risk reduction in major adverse cardiovascular events such as heart attack, nonfatal stroke, or cardiovascular death.

Trulicity is the first type 2 diabetes medicine approved to reduce cardiovascular events in adults. It was originally approved in 2014 to improve blood sugar in adults with type 2 diabetes.